Drug Profile

EBC 1013

Alternative Names: EBC-1013; WH-1 - QBiotics; WH1

Latest Information Update: 06 Sep 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator QBiotics
Class Skin disorder therapies; Small molecules
Mechanism of Action Cell movement activators; Signal transduction pathway stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

30 Jun 2023 Phase-I/II clinical trials in Leg ulcer in Australia (unspecified route) (ACTRN12624000544572p)
30 Jun 2023 Phase-I/II clinical trials in Leg ulcer in United kingdom (unspecified route)
08 Apr 2023 Preclinical development in Wounds is ongoing in Unknown location (Qbiotics pipeline, April 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com